XOMA Corp

NASDAQ: XOMA
$26.15
-$1.24 (-4.5%)
Real Time Data Delayed 15 Min.

XOMA Stock Chart and Intraday Price

XOMA Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 2200 POWELL STREET, SUITE 310, EMERYVILLE, CA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 286.05M USD
Shares Outstanding 11,487,800
XOMA Corp is a pioneering biotech royalty aggregator with a global presence, including Europe, the United States, and the Asia Pacific. Founded in 1981 and based in Emeryville, California, XOMA plays a crucial role in advancing human health by acquiring future economic rights of pre-commercial therapeutic candidates. The company specializes in identifying and investing in early to mid-stage clinical assets, particularly those in Phase 1 and 2, which show promise for commercial success. XOMA's diverse portfolio underscores its commitment to fostering innovation in the biotech industry.

XOMA Articles

Oasis Petroleum, Stem, Tata Motors, Tesla, Textron and Two Harbors Investment were among Tuesday afternoon's analyst upgrades and downgrades.
The top analyst upgrades, downgrades and other research calls from Tuesday include Biogen, Carbonite, Celgene, Emerson Electric, Kinder Morgan, Netflix and UnitedHealth.
The top analyst upgrades, downgrades and other research calls from Tuesday include Chesapeake Energy, Lululemon Athletica, Oracle, US Steel, Walt Disney and YogaWorks.
24/7 Wall St. has collected several catalysts that are coming up on the calendar in the month of December.
The top analyst upgrades, downgrades and initiations seen on Monday morning include Ciena, CME Group, Energy Transfer, NVIDIA and U.S. Steel.
Last week, a few biotech companies made absolutely massive runs, while others had serious falls.
One thing all biotech investors know is that if a binary event like clinical data goes wrong on a company relying on one specific product, then the end may not be that far behind.
Thursday's top analyst upgrades, downgrades and initiations include Boeing, EMC, Hertz, Qualcomm, SanDisk, Twitter and XOMA.
XOMA Corp. (NASDAQ: XOMA) stumbled in trading Wednesday morning, perhaps fell off a cliff might be more accurate.
Recently, biotech stocks have been getting stung pretty good, and now may be a good time to look at companies with pending catalysts.
A new report from RBC focuses on top small-cap biotech stocks with key data readouts coming in 2015. Binary events are often the key element in moving a biotech stock higher.
The steep sell-off at the start of the week certainly enticed some insiders to step up to the plate and add to their positions.
With the 2014 trading year coming to an end last week, the pace of inside selling picked up a bit as insiders continued to sell stock in time to put it on the 2014 ledger and tax forms.
In a week when the markets were putting in some all-time highs, many insiders stayed on the sidelines, which is yet another positive as the bull market looks to continue as we head into 2015.
Insider selling still lags the buyers in overall dollar amount and shares traded. It is possible that many insiders with planned selling programs have already taken some chips off the table.